The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Publications
Radiologic evaluation of pulmonary injury following carmustine- and cyclophosphamide-based preparative regimen for autologous peripheral blood stem cell transplantation in children.
Pediatric radiology 2018 12;48;1875-1883 — 2018 12 — 1875-1883
BCNU toxicity presenting with a large pericardial and pleural effusion.
Annals of transplantation 2008;13;44-7 — 2008 — 44-7
Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P, Malcovati L, Nascimbene C, Varettoni M, Volpini E, Klersy C, Bernasconi C
Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Bone marrow transplantation 2000 Feb;25;309-13 — 2000 Feb — 309-13
Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment.
Bone marrow transplantation 1997 Dec;20;1063-7 — 1997 Dec — 1063-7
The nitrosoureas and pulmonary toxicity.
Cancer treatment reviews 1981 Jun;8;111-25 — 1981 Jun — 111-25
Early pulmonary toxicity after administration of high-dose BCNU.
Cancer treatment reports 1981 Jan-Feb;65;39-44 — 1981 Jan-Feb — 39-44